INT MEDICAL (01501): Proposes to issue no more than 37,270,600 A shares in total.

INT MEDICAL (01501) announced that the Board has considered and approved the proposed A Share Issuance, in order to leverage the synergistic advantages of the Hong Kong and A-share capital markets, establish a dual capital operation platform, broaden financing channels, optimize the Company's capital structure, enhance comprehensive competitiveness, and achieve the Company's long-term steady development. Type of shares: RMB ordinary shares (A Shares), with a par value of RMB1.00 per share. The A Shares, which will be traded in RMB and listed on the ChiNext Board of the Shenzhen Stock Exchange, belong to the same class as the existing issued H Shares listed on the Stock Exchange. The A Shares will rank pari passu with the existing H Shares listed on the Stock Exchange, with the same par value and the same rights to voting, dividends and return of assets. The total number of RMB ordinary shares (A Shares) proposed to be publicly issued this time shall not exceed 37,270,600 A Shares (excluding A Shares issued upon exercise of the over-allotment option), representing not more than approximately 17.65% of the Company's total issued share capital as at the date of this announcement, and not more than 15% of the Company's total issued share capital as enlarged by the allotment and issue of A Shares. The issuance will consist entirely of new shares to be publicly issued and does not involve any public offer of shares by shareholders. The Company and the lead underwriter may use the over-allotment option, and the number of A Shares issued upon exercise of the over-allotment option shall not exceed 15% of the proposed number of A Shares to be issued (before exercise of the over-allotment option). The final number of A Shares to be issued shall be determined by the Board, authorized by the shareholders at the Company's general meeting, in consultation with the sponsor (lead underwriter) within the quota approved by the Shenzhen Stock Exchange and registered with the consent of the CSRC, based on specific circumstances. Assuming the over-allotment option is exercised in full and there are no other changes in the Company's issued share capital, the maximum number of A Shares to be issued will be 42,861,200 shares, representing approximately 20.29% of the Company's total issued share capital as at the date of this announcement and 16.87% of the Company's total issued share capital as enlarged by the allotment and issue of A Shares. The issue price will be determined by way of price inquiry. The Board and the lead underwriter, authorized by the shareholders at the Company's general meeting, will determine the issue price through a preliminary price inquiry; or, after determining the price range through the preliminary price inquiry, determine the issue price through cumulative bidding price inquiry. The Directors believe that the A Share Issuance will enable the Company to leverage the synergistic advantages of the Hong Kong and A-share capital markets, establish a dual capital operation platform, fully utilize the prominent advantages of the A-share capital market in terms of abundant liquidity and diversified financing channels, and support the development and industrial layout of the Company's core medical device business. On the one hand, the A Share Issuance can raise sufficient funds to focus on core technology research and development, product pipeline expansion and industrial ecosystem integration, continuously consolidating technical barriers and product competitiveness; on the other hand, it will help further enhance brand influence and customer trust, deepen the domestic industry market layout, and optimize the Company's governance structure and information disclosure standards. With the H+A dual-listing structure, the Company will effectively broaden financing space, optimize capital structure, enhance comprehensive competitiveness, seize opportunities in the development of the medical device industry, consolidate its industry-leading position, and achieve long-term steady development.